The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
UNITAID partners to bring newer and more effective HIV treatment options to countries where they are needed most.
Key HIV drugs added to the list of medicines critical to public health, including tenofovir for HIV prevention, and dolutegravir.
The country with the third largest HIV epidemic moves to a test-and-treat strategy that aims to get everyone on antiretroviral therapy.
The first trials enhancing orally-taken antiretroviral treatment with Solid Drug Nanoparticle technology have produced “incredibly promising” results.
The first ever study evaluating the decentralising of HIV care through antiretroviral treatment (ART) distribution centres shows low rates of patient loss in the city.
‘Surprising’ research from Conference on Retroviruses and Opportunistic Infections (CROI) shows drug resistance does not impact test-and-treat roll-out in South Africa – at least in the short term.
Mixed-status couples using PrEP could benefit from HIV self-testing as a way to quickly diagnose any new infections and reduce frequency of clinic visits.
Identifying individuals at high risk of disengaging with HIV care remains an important strategy for realising the benefits of antiretroviral treatment for public health.
HIV is more proactively monitored among urban HIV patients than rural patients, and drug resistance and treatment failure is less prevalent. However outcomes for second line treatment remain similar.
Treatment scale-up has had major public health benefits. But where resources are scarce, interventions to keep people in care could be more cost-effective than moving to treat everybody living with HIV after diagnosis.